Tevogen Bio(TVGN) - 2025 Q4 - Annual Report

Financial Condition - The company has a limited operating history with no products approved for commercial sale and has never generated revenue from product sales, resulting in significant losses[17] - The company is relying on an additional $7.0 million of grant funding that has not yet been received to meet liquidity needs[17] - The company anticipates requiring substantial additional financing to achieve business objectives and fund operations[17] - Substantial additional financing will be required to achieve business objectives and fund operations[17] Regulatory Challenges - The FDA regulatory approval process for product candidates is lengthy and time-consuming, which may delay commercialization[17] - The FDA regulatory approval process is lengthy and time-consuming, which may delay product development[17] - The company faces extensive ongoing regulatory requirements and review after obtaining regulatory approval for its product candidates[17] - There may be substantial delays and disruptions in the development of product candidates due to regulatory complexities[17] Product Development Risks - The company is highly dependent on its first product candidate, TVGN 489, for the treatment of COVID-19 and Long COVID[13] - The company is highly dependent on its first product candidate, TVGN 489, for future success[17] - Initial results from clinical trials may not be predictive of future results, and the company may encounter substantial delays in development[17] - The company has limited experience in designing and implementing preclinical and clinical trials, which are complex and costly[17] - The company may face difficulties in enrolling patients for clinical trials, impacting trial outcomes[17] Manufacturing and Market Approval Risks - Manufacturing of cell therapies involves numerous risks, and establishing manufacturing capabilities may not be successful[20] - The company may not obtain marketing approval for product candidates due to failures by third parties[20] Stock Market Risks - The price of the company's common stock may fluctuate significantly, and failure to meet Nasdaq's listing requirements could lead to delisting[20]